GLP-1 receptor agonists and skeletal muscle: The risk of sarcopenic obesity and the role of resistance training. A narrative review
DOI:
https://doi.org/10.12775/QS.2026.69.74557Keywords
GLP-1 receptor agonists, semaglutide, tirzepatide, skeletal muscle, sarcopenic obesity, resistance training, body compositionAbstract
Background. GLP-1 receptor agonists (GLP-1 RAs) and incretin-based co-agonists have transformed the management of obesity and type 2 diabetes, producing weight loss approaching that of bariatric surgery. Attention has shifted from the quantity of weight lost to its quality - the proportion of fat versus skeletal muscle (lean) mass removed. A meaningful fraction of GLP-1 RA-induced loss is lean tissue, raising concern that these agents may unmask or aggravate sarcopenic obesity
Aim. To synthesise evidence on GLP-1 RAs’ effect on skeletal muscle and body composition, characterise the risk of sarcopenic obesity, and appraise resistance training, nutritional and pharmacological countermeasures.
Material and methods. A review used PubMed and Google Scholar. RCTs, observational studies, reviews, meta-analyses and relevant preclinical research published in English between 2018 and 2026 were analysed.
Results. Absolute lean-mass reductions represent ~20-40% of total weight lost. Contemporary imaging suggests these changes are largely adaptive - commensurate with weight loss - rather than pathological. Principal drivers are reduced energy and protein intake from appetite suppression, catabolic drive, inactivity and anabolic resistance, not direct toxicity. Resistance training with adequate protein (~1.2-1.6 g/kg/day) is the best-established preservation strategy, and activin/myostatin blockers (e.g. bimagrumab) reduce lean-mass loss in early trials. A meta-analysis of tirzepatide trials reported improved physical function versus placebo.
Conclusions. Skeletal-muscle loss is a real, quantifiable consequence of GLP-1 RA therapy, though heterogeneous and often adaptive. Older adults, patients with type 2 diabetes, peri- and postmenopausal women, and those with low baseline muscle mass are at greatest risk. Structured resistance training with optimised protein should accompany therapy in at-risk patients; muscle-preserving pharmacotherapy is a rapidly evolving frontier.
References
1. Look M., Dunn J. P., Kushner R. F., Cao D., Harris C., Gibble T. H., Stefanski A., Griffin R. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 27:2720-2729. https://doi.org/10.1111/dom.16275
2. Linge J., Birkenfeld A. L., Neeland I. J. (2024). Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation, 150(16):1288–1298. https://doi.org/10.1161/CIRCULATIONAHA.124.067676
3. Locatelli J. C., Costa J. G., Haynes A., Naylor L. H., Fegan P. G., Yeap,B. B., Green D. J. (2024). Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care, 47(10):1718–1730. https://doi.org/10.2337/dci23-0100
4. Barana L., De Fano M., Cavallo M., Manco M., Prete D., Fanelli C. G., Porcellati F., Pippi R. (2026). Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review. Nutrients, 18:131. https://doi.org/10.3390/nu18010131
5. Sardeli A. V., Komatsu T. R., Mori M. A., Gáspari A. F., Chacon-Mikahil M. P. T. (2018). Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A systematic Review and Meta-Analysis. Nutrients, 10(4):423. https://doi.org/10.3390/nu10040423
6. Heymsfield S. B., Aronne L. J., Montgomery P., Klickstein L. B., Coleman L. A., Dole K., Mindeholm L., Spruill S., Li X., Attie K. M. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 clinical trial. Nature Medicine 32, 869–882. https://doi.org/10.1038/s41591-026-04204-0
7. Schmidt P. H. S., Nonato de Souza V. S., Machado L. G., Rodrigues J. V. A., Ramos da Cruz J. V., Nonato de Souza L. S., dos Santos B. E., Hohl A., Ronsoni M. F., van de Sande-Lee S. (2026) Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 28:3335-3343 https://doi.org/10.1111/dom.70529
8. Jastreboff A. M., Aronne L. J., Ahmad N. N., Wharton S., Connery L., Alves B., Kiyosue A., Zhang S., Liu B., Bunck M. C., Stefanski A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387:205–216. https://doi.org/10.1056/NEJMoa2206038
9. Jastreboff A. M., Kaplan L. M., Frías J. P., Wu Q., Du Y., Gurbuz S., Coskun T., Haupt A., Milicevic Z., Hartman M. L. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A phase 2 trial. New England Journal of Medicine 389:514–526. https://doi.org/10.1056/NEJMoa2301972
10. Tinsley G. M., Heymsfield S. B. (2024). Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society, 8(11):164. https://doi.org/10.1210/jendso/bvae164
11. Kim G., Kim J. H. (2020). Impact of Skeletal Muscle Mass on Metabolic Health. Endocrinology and Metabolism 35(1):1–6. https://doi.org/10.3803/EnM.2020.35.1.1
12. Srikanthan P., & Karlamangla A. S. (2014). Muscle Mass Index as a Predictor of Longevity in Older Adults. The American Journal of Medicine, 127(6):547–553. https://doi.org/10.1016/j.amjmed.2014.02.007
13. Kirk B., Cawthon P. M., Arai H., Ávila-Funes J. A., Barazzoni R., Bhasin S., Binder E. F., Bruyere O., Cederholm T., Chen L-K., Cooper C., Duque G., Fielding R. A., Guralnik J., Kiel D. P., Landi F., Reginster J-Y., Sayer A. A., Visser M., von Haehling S., Woo J., Cruz-Jentoft A. J., The Global Leadership Initiative in Sarcopenia (GLIS) group , The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS), (2024). Age and Ageing, 53, afae052. https://doi.org/10.1093/ageing/afae052
14. Voulgaridou G., Tyrovolas S., Detopoulou P., Tsoumana D., Drakaki M., Apostolou T., Chatziprodromidou I. P., Papandreou D., Giaginis C., Papadopoulou S. K. (2024). Diagnostic Criteria and Measurement Techniques of Sarcopenia: A Critical Evaluation of the Up-to-Date Evidence. Nutrients, 16(3):436. https://doi.org/10.3390/nu16030436
15. Donini L. M., Busetto L., Bischoff S. C., Cederholm T., Ballesteros-Pomar M. D., Batsis J. A., Bauer J. M., Boirie Y., Cruz-Jentoft A. J., Dicker D., Frara S., Frühbeck G., Genton L., Gepner Y., Giustina A., Gonzalez M. C., Han H-S., Heymsfield S. B., Higashiguchi T., Laviano A., Lenzi A., Nyulasi I., Parrinello E., Poggiogalle E., Prado C. M., Salvador J., Rolland Y., Santini F., Serlie M. J., Shi H., Sieber C. C., Siervo M., Vettor R., Villareal D. T., Volkert D., Yu J., Zamboni M., Barazzoni R. (2022). Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clinical Nutrition, 41:990–1000. https://doi.org/10.1016/j.clnu.2021.11.014
16. Montalvão-Sousa T. M., Ferreira P. A., Colombelli N. L., de Carvalho K. M. B., Blazevich A. J., Lima R. M. (2024). Sarcopenic obesity defined by the ESPEN and EASO consensus statement in older women: Risk of falls and bone mineral density implications. Archives of Gerontology and Geriatrics, 124:105444. https://doi.org/10.1016/j.archger.2024.105444
17. Schluessel S., Huemer M.-T., Peters A., Drey M., Thorand, B. (2023). Sarcopenic obesity using the ESPEN and EASO consensus statement criteria of 2022 – Results from the German KORA-Age study. Obesity Research & Clinical Practice, 17(4):349–352. https://doi.org/10.1016/j.orcp.2023.08.002
18. Domagała S., Wiater Z., Włodarczyk A., Brankowska K., Jakubowska M., Olejnik M., Tymińska P., Górka P. A., Frączek J., & Kądziołka W. (2026). The Impact of GLP-1 Receptor Agonists on Body Composition and Musculoskeletal Integrity: A Review of Mechanisms, Protective Strategies, and Clinical Perspectives. Quality in Sport, 53, 69771. https://doi.org/10.12775/QS.2026.53.69771
19. Beavers K. M., Avery A. E., Shankaran M., Evans W. J., Lynch S. D., Dwyer C., Howard M., Beavers D. P., Weaver A. A., Lenchik L, Cawthon P. M. (2023). Application of the D3-creatine muscle mass assessment tool to a geriatric weight loss trial: A pilot study. Journal of Cachexia, Sarcopenia and Muscle, 14: 2350-2358 https://doi.org/10.1002/jcsm.13322
20. Orwoll E. S., Peters K. E., Hellerstein M., Cummings S. R., Evans W. J., Cawthon P. M. (2020). The Importance of Muscle Versus Fat Mass in Sarcopenic Obesity: A Re-evaluation Using D3-Creatine Muscle Mass Versus DXA Lean Mass Measurements. The Journals of Gerontology: Series A, 75:1362-1368. https://doi.org/10.1093/gerona/glaa064
21. Caturano A., Amaro A., Berra C. C., Conte C. (2025). Sarcopenic obesity and weight loss-induced muscle mass loss. Current Opinion in Clinical Nutrition and Metabolic Care, 28:339-350. https://doi.org/10.1097/MCO.0000000000001131
22. Wilding J. P. H., BatterhamR. L., Calanna S., Davies M., Van Gaal L. F., Lingvay I., McGowan B. M., Rosenstock J., Tran M. T. D., Wadden T. A., Wharton S., Yokote K., Zeuthen N., Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11):989–1002. https://doi.org/10.1056/NEJMoa2032183
23. Gross K., Brinkmann C. (2024). Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss. Frontiers in Endocrinology, 15, 1449653. https://doi.org/10.3389/fendo.2024.1449653
24. Reizer B., Botto Z., Krystek K., Felisiak P., Kowalczyk D., Śliwa Z., Ślazyk D. A. (2026). Semaglutide-Induced Weight Loss: Consequences for Muscle Mass and Functional Outcomes. Journal of Education, Health and Sport, 88, 68182. https://doi.org/10.12775/JEHS.2026.88.68182
25. Prokopidis K., Chambers E., Ní Lochlainn M., Witard O. C. (2021). Mechanisms Linking the Gut–Muscle Axis With Muscle Protein Metabolism and Anabolic Resistance: Implications for Older Adults at Risk of Sarcopenia. Frontiers in Physiology, 12: 770455. https://doi.org/10.3389/fphys.2021.770455
26. Choi R. H., Karasawa T, Meza C. A., Mashek A., Manuel A. M., Nikolova L. S., Fisher-Wellman K. H., Cox J. E., Chaix A., Funai K. (2025). Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle. Obesity, 33:974–985. https://doi.org/10.1002/oby.24274
27. Mechanick J. I., Butsch W. S., Christensen S. M., Hamdy O., Li Z., Prado C. M., Heymsfield S. B. (2025). Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obesity Reviews, 26(1) e13841. https://doi.org/10.1111/obr.13841
28. Lundgren J. R., Janus C., Jensen S. B. K., Juhl C. R., Olsen L. M., Christensen R. M., Svane M. S., Bandholm T., Bojsen-Møller K. N., Blond M. B., Jensen J-E. B., Stallknecht B. M., Holst J. J., Madsbad S., Torekov, S. S. (2021). Healthy Weight Loss Maintenance With Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 384:1719–1730. https://doi.org/10.1056/NEJMoa2028198
29. Alawadhi A. A., Alroudhan D., Alsaeed D. J., Almarshad B. W., Alshehabi D. H., Allahou B., Mashankar A., Al Ozairi E., Gray S. (2026) LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. BMJ Open 16:116911 https://doi.org/10.1136/bmjopen-2026-116911
30. Nunn E., Jaiswal N., Gavin M., Uehara K., Stefkovich M., Drareni, K., Calhoun R., Lee M., Holman C. D., Baur J. A., Seale P., Titchenell P. M. (2024). Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Molecular Metabolism, 80:101880. https://doi.org/10.1016/j.molmet.2024.101880
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Roksana Milaniuk, Aleksandra Drzewiecka, Szymon Daniszewski, Izabela Czerny, Beata Surówka, Wioleta Pluta, Krzysztof Talarowski, Piotr Tylec, Arkadiusz Ściubak, Jakub Bryl, Aleksandra Pacek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 213
Number of citations: 0
